{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:44:54Z","timestamp":1775706294340,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100017046","name":"the University of Maryland School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has ushered in an era of short-duration treatment with high effectiveness across varied patient populations. In the ASCEND investigation, treatment with DAA was efficacious when delivered by nonspecialist and specialist providers. However, long-term outcomes after initial treatment are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the long-term outcomes after DAA treatment independently provided by nurse practitioners, primary care physicians, or specialist physicians using DAA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Twelve urban, federally qualified health centers in the District of Columbia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>A total of 551 patients treated for HCV in the ASCEND investigation (A Phase IV Pilot Study to Assess of Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>None.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Measurements<\/jats:title>\n                  <jats:p>Sustained viral response (SVR12), reinfection, retreatment, death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this large sample of majority Black individuals receiving care at community-based centers, there was an initial 87% rate of SVR, and after 5 years of follow up, an additional 6.5% of participants were found to be cured. This included individuals originally lost to follow up whose subsequent testing confirmed SVR12, and those with successful retreatment after initial treatment failure. There was a 70% rate of testing for reinfection, with 2 identified reinfections. Treatment outcomes were not associated with original treating provider type.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Limitations<\/jats:title>\n                  <jats:p>As a retrospective analysis, these findings are limited by the availability of data in the electronic medical record.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DAA is an effective treatment for HCV and can safely be prescribed by multiple provider types, with favorable long-term outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf174","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:13:19Z","timestamp":1742731999000},"source":"Crossref","is-referenced-by-count":2,"title":["Sustained Impact of Task-shifting HCV Treatment to Nonspecialist Providers: 5-Year Follow Up of the ASCEND Investigation"],"prefix":"10.1093","volume":"12","author":[{"given":"Sarah","family":"Mollenkopf","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-4871","authenticated-orcid":false,"given":"Elana","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-8655","authenticated-orcid":false,"given":"Geb","family":"Teferi","sequence":"additional","affiliation":[{"name":"Unity Healthcare, Inc. , Washington, DC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Silk","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivya","family":"George","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3688-021X","authenticated-orcid":false,"given":"Henry","family":"Masur","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7471-0812","authenticated-orcid":false,"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-3597","authenticated-orcid":false,"given":"Sarah","family":"Kattakuzhy","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2025052712085805200_ofaf174-B1","author":"Hepatitis C Surveillance in the United States"},{"key":"2025052712085805200_ofaf174-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"key":"2025052712085805200_ofaf174-B3","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2105\/AJPH.2014.302142","article-title":"Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics","volume":"104","author":"Zibbell","year":"2014","journal-title":"Am J Public Health"},{"key":"2025052712085805200_ofaf174-B4","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years: Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025052712085805200_ofaf174-B5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025052712085805200_ofaf174-B6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"N Engl J Med"},{"key":"2025052712085805200_ofaf174-B7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12879-018-3125-6","article-title":"Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study","volume":"18","author":"Lanini","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025052712085805200_ofaf174-B8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement","volume":"323","author":"US Preventive Services Task Force","year":"2020","journal-title":"JAMA"},{"key":"2025052712085805200_ofaf174-B9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017\u2013March 2020","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025052712085805200_ofaf174-B10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: hepatitis C treatment among insured adults\u2014United States, 2019\u20132020","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025052712085805200_ofaf174-B11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.15585\/mmwr.mm7226a3","article-title":"Hepatitis C virus clearance cascade\u2014United States, 2013\u20132022","volume":"72","author":"Wester","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025052712085805200_ofaf174-B12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A national hepatitis C elimination program in the United States: a historic opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"2025052712085805200_ofaf174-B13","author":"2023 National Snapshot Report"},{"key":"2025052712085805200_ofaf174-B14","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025052712085805200_ofaf174-B15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/M17-1073","article-title":"Curing hepatitis C virus infection: best practices from the U.S. Department of Veterans Affairs","volume":"167","author":"Belperio","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025052712085805200_ofaf174-B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025052712085805200_ofaf174-B17","author":"Group S. Hepatitis C Treatment Restrictions"},{"key":"2025052712085805200_ofaf174-B18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025052712085805200_ofaf174-B19"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf174\/62523948\/ofaf174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf174\/62523948\/ofaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf174\/62523948\/ofaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:09:33Z","timestamp":1748362173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf174\/8090458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf174","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,22]]},"article-number":"ofaf174"}}